Effects of irradiation using a radioisotope-filled balloon on tissue hyperplasia caused by stent placement in a canine urethral model

Acta Radiol. 2006 May;47(4):436-43. doi: 10.1080/02841850600557125.

Abstract

Purpose: To evaluate 20 Gy and 40 Gy of intraluminal beta-irradiation using a 188Re-7mercaptoacetyltriglycine (MAG3)-filled balloon catheter to reduce tissue hyperplasia caused by covered stent placement for 12 weeks of follow-up in a canine urethral model.

Material and methods: Ten dogs underwent 188Re-MAG3-filled balloon dilatation immediately after stent placement; 20 Gy at 1-mm tissue depth in group I (n = 5) and 40 Gy in group II (n = 5), whereas 5 dogs (group III) underwent conventional balloon dilatation only.

Results: There were no significant differences among the three groups for percentage diameter of stenosis, although this was highest in group III. There was a tendency toward lower mean thickness of the epithelial layer and the papillary projection for out-stent area, and thickness of the papillary projection and degree of inflammatory cells for instent area in groups I and II compared with group III. Thickness of the papillary projection in out-stent area was significantly different among the three groups (P = 0.031). It was significantly less thick in group I than in group III (P < 0.05), whereas group II was not significantly different from group III.

Conclusion: 188Re-MAG3-filled balloon dilatation has the potential to reduce tissue hyperplasia after 12 weeks of follow-up in a canine urethral model. The use of 20 Gy compared to 40 Gy did not show significant differences.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brachytherapy / instrumentation*
  • Brachytherapy / methods
  • Catheterization / methods*
  • Disease Models, Animal
  • Dogs
  • Dose-Response Relationship, Radiation
  • Follow-Up Studies
  • Hyperplasia / etiology
  • Hyperplasia / radiotherapy*
  • Oligopeptides / therapeutic use*
  • Organometallic Compounds / therapeutic use*
  • Radiopharmaceuticals / therapeutic use*
  • Stents / adverse effects
  • Treatment Outcome
  • Urethra / pathology
  • Urethra / radiation effects
  • Urethral Stricture / etiology
  • Urethral Stricture / radiotherapy*

Substances

  • Oligopeptides
  • Organometallic Compounds
  • Radiopharmaceuticals
  • rhenium-mercaptoacetyltriglycine